



ASX Announcement – AVH

Appendix 3Y and correction to notifiable interests of Mr McNamara

Valencia, California, USA, August 26, 2025; and Melbourne, Australia, August 27, 2025: AVITA Medical, Inc. (ASX: AVH, NASDAQ: RCEL) (the "Company") attaches to this announcement an Appendix 3Y in respect of a change to the notifiable interests of Mr Robert McNamara that occurred as a result of an on-market purchase of shares of common stock in the Company ("Shares") on the NASDAQ Stock Market LLC ("NASDAQ") on 19 August 2025 (United States) / 20 August 2025 (Australia).

The Company wishes to advise that it has come to the Company's attention that it did not lodge an Appendix 3Y in relation to the on-market purchase of 10,000 Shares on NASDAQ by Mr McNamara on 19 August 2024 (United States) / 20 August 2024 (Australia) ("Additional Shares") and that, as a result, the Appendix 3Ys that were lodged with ASX in respect of Mr McNamara's notifiable interests in February, March and June 2025 did not reflect Mr McNamara's holding of the Additional Shares.

The Company confirms that the Additional Shares were not acquired during a closed period where prior written clearance was required and that the Additional Shares were purchased on-market on NASDAQ by Mr McNamara at a price of USD9.00 per Share.

The attached Appendix 3Y reflects Mr McNamara's holding of the Additional Shares (both in the "No. of securities held prior to change" and in the "No. of securities held after change").

The Company confirms that it and its directors are aware of their respective obligations under the ASX Listing Rules and considers that the failure to lodge the Appendix 3Y in relation to the Additional Shares was an isolated administrative oversight.

About AVITA Medical, Inc.

AVITA Medical® is a leading therapeutic acute wound care company delivering transformative solutions. Our technologies are designed to optimize wound healing, effectively accelerating the time to patient recovery. At the forefront of our platform is the RECELL® System, approved by the U.S. Food and Drug Administration for the treatment of thermal burn and trauma wounds. RECELL harnesses the healing properties of a patient's own skin to create Spray-On Skin™ Cells, offering an innovative solution for improved clinical outcomes at the point-of-care. In the U.S., AVITA Medical also holds the exclusive rights to manufacture, market, sell, and distribute PermeaDerm®, a biosynthetic wound matrix, and the exclusive rights to market, sell, and distribute Cohealix™, an AVITA Medical-branded collagen-based dermal matrix.

In international markets, the RECELL System is approved to promote skin healing in a wide range of applications including thermal burn and trauma wounds. The RECELL System, excluding RECELL GO®, is TGA-registered in Australia, has received CE mark approval in Europe, and has PMDA approval in Japan.

To learn more, visit www.avitamedical.com.

Investor & Media Contact:

Ben Atkins

Phone +1-805-341-1571

investor@avitamedical.com

media@avitamedical.com

Authorized for release by the Chief Financial Officer of the Company.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity: AVITA Medical, Inc. ("Company")
ARBN: 641 288 155

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Robert McNamara
Date of last notice	11 June 2025

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	N/A
Date of change	19 August 2025 (United States) / 20 August 2025 (Australia)
No. of securities held prior to change	13,480 unquoted restricted stock units ("RSUs") 53,291 shares of common stock in the Company quoted on the NASDAQ Stock Market LLC ("Shares") 7,092 options expiring 7 June 2033, ex USD \$14.17 3,943 options expiring 6 June 2034, ex USD \$9.51 4,295 options expiring 22 January 2035, ex USD \$8.73
Class	Shares
Number acquired	10,000 Shares

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Number disposed	N/A
Value/Consideration <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	USD \$5.00 per Share
No. of securities held after change	13,480 RSUs 63,291 Shares 7,092 options expiring 7 June 2033, ex USD \$14.17 3,943 options expiring 6 June 2034, ex USD \$9.51 4,295 options expiring 22 January 2035, ex USD \$8.73
Nature of change <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	On-market purchase on the NASDAQ Stock Market LLC

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	N/A

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Interest after change	N/A
------------------------------	-----

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See chapter 19 for defined terms.